James Heyward

1.8k total citations · 1 hit paper
23 papers, 946 citations indexed

About

James Heyward is a scholar working on Public Health, Environmental and Occupational Health, Economics and Econometrics and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, James Heyward has authored 23 papers receiving a total of 946 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Public Health, Environmental and Occupational Health, 9 papers in Economics and Econometrics and 5 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in James Heyward's work include Health Systems, Economic Evaluations, Quality of Life (8 papers), Opioid Use Disorder Treatment (7 papers) and Diabetes Treatment and Management (5 papers). James Heyward is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (8 papers), Opioid Use Disorder Treatment (7 papers) and Diabetes Treatment and Management (5 papers). James Heyward collaborates with scholars based in United States, Netherlands and Sweden. James Heyward's co-authors include G. Caleb Alexander, Omar Mansour, Randall S. Stafford, Dima M. Qato, Christopher M. Jones, Thomas J. Moore, Gerard F. Anderson, Jonothan C. Tierce, Sonal Singh and G. Caleb Alexander and has published in prestigious journals such as JAMA, Annals of Internal Medicine and Journal of the American College of Cardiology.

In The Last Decade

James Heyward

22 papers receiving 937 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US

2020 313 citations G. Caleb Alexander, James Heyward et al. JAMA Network Open profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Heyward United States	15	353	207	189	163	141	23	946
Ximena Camacho Canada	16	443 1.3×	377 1.8×	184 1.0×	231 1.4×	71 0.5×	45	1.9k
Zhan Yao Canada	18	246 0.7×	141 0.7×	52 0.3×	89 0.5×	48 0.3×	38	1.1k
James M. Dupree United States	25	539 1.5×	332 1.6×	87 0.5×	120 0.7×	63 0.4×	92	1.8k
Elayne Livote United States	18	336 1.0×	186 0.9×	72 0.4×	33 0.2×	39 0.3×	27	1.2k
Kosuke Iwasaki Japan	15	287 0.8×	94 0.5×	129 0.7×	95 0.6×	24 0.2×	62	995
Joanne LaFleur United States	18	95 0.3×	127 0.6×	147 0.8×	307 1.9×	45 0.3×	58	1.4k
Luke Boulanger United States	22	89 0.3×	88 0.4×	55 0.3×	201 1.2×	101 0.7×	68	1.4k
Jaana E. Martikainen Finland	19	294 0.8×	81 0.4×	34 0.2×	77 0.5×	83 0.6×	44	1.3k
Juan Garduño‐Espinosa Mexico	19	133 0.4×	140 0.7×	81 0.4×	108 0.7×	28 0.2×	128	1.0k
Mikael Hoffmann Sweden	15	161 0.5×	111 0.5×	57 0.3×	189 1.2×	31 0.2×	49	973

Countries citing papers authored by James Heyward

Since Specialization

Citations

This map shows the geographic impact of James Heyward's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Heyward with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Heyward more than expected).

Fields of papers citing papers by James Heyward

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Heyward. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Heyward. The network helps show where James Heyward may publish in the future.

Co-authorship network of co-authors of James Heyward

This figure shows the co-authorship network connecting the top 25 collaborators of James Heyward. A scholar is included among the top collaborators of James Heyward based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Heyward. James Heyward is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heyward, James & Jodi B Segal. (2025). Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology—Reply. JAMA Oncology. 11(12). 1550–1550.

Lesko, Catherine R., Lauren C. Zalla, James Heyward, Corey Joseph, & Jessie K. Edwards. (2023). Weighing Risks and Benefits in the Presence of Competing Risks. Current Epidemiology Reports. 10(4). 221–239. 1 indexed citations

Segal, Jodi B, Ravi Varadhan, Rolf H. H. Groenwold, et al.. (2023). Assessing Heterogeneity of Treatment Effect in Real-World Data. Annals of Internal Medicine. 176(4). 536–544. 15 indexed citations

Jha, Kunal, Zeina Dardari, James Heyward, et al.. (2022). National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020. Journal of the American Heart Association. 11(9). e023811–e023811. 90 indexed citations

Akenroye, Ayobami, James Heyward, Corinne Keet, & G. Caleb Alexander. (2021). Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals. The Journal of Allergy and Clinical Immunology In Practice. 9(11). 3969–3976. 43 indexed citations

Heyward, James, et al.. (2021). CARDIOLOGIST USE OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS SINCE RELEASE OF FAVORABLE CARDIOVASCULAR OUTCOMES TRIALS: A NATIONAL STUDY. Journal of the American College of Cardiology. 77(18). 1468–1468. 2 indexed citations

Foti, Kathryn, et al.. (2021). Primary care physicians’ preparedness to treat opioid use disorder in the United States: A cross-sectional survey. Drug and Alcohol Dependence. 225. 108811–108811. 30 indexed citations

Heyward, James, et al.. (2021). Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019. Diabetes Obesity and Metabolism. 23(8). 1843–1850. 9 indexed citations

Sarkar, Sudipa, James Heyward, G. Caleb Alexander, & Rita R. Kalyani. (2021). Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020. JAMA Network Open. 4(10). e2128782–e2128782. 21 indexed citations

10.

Moore, Thomas J., James Heyward, Gerard F. Anderson, & G. Caleb Alexander. (2020). Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study. BMJ Open. 10(6). e038863–e038863. 55 indexed citations

11.

Heyward, James, et al.. (2020). Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis. PLoS ONE. 15(6). e0234065–e0234065. 70 indexed citations

12.

Heyward, James, et al.. (2020). Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018. Annals of Internal Medicine. 173(12). 956–963. 3 indexed citations

13.

Heyward, James, et al.. (2019). Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products. JAMA. 321(7). 676–676. 29 indexed citations

14.

Compton, Wilson M., James Heyward, Jan L. Losby, et al.. (2018). Prescription Drug Coverage for Treatment of Low Back Pain Among U.S. Medicaid, Medicare Advantage and Commercial Insurers. Value in Health. 21. S258–S259. 1 indexed citations

15.

Heyward, James, William V. Padula, Jonothan C. Tierce, & G. Caleb Alexander. (2018). The Value of U.S. Pharmacopeial Standards: A Review of the Literature. Journal of Pharmaceutical Sciences. 107(10). 2611–2617. 9 indexed citations

16.

Mayo‐Wilson, Evan, et al.. (2018). Clinical trial registration and reporting: a survey of academic organizations in the United States. BMC Medicine. 16(1). 60–60. 31 indexed citations

17.

Heyward, James, Christopher M. Jones, Wilson M. Compton, et al.. (2018). Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers. JAMA Network Open. 1(6). e183044–e183044. 111 indexed citations

18.

Lin, Dora H., Christopher M. Jones, Wilson M. Compton, et al.. (2018). Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers. JAMA Network Open. 1(2). e180235–e180235. 43 indexed citations

19.

Lê, Jimmy T., Susan Hutfless, Tianjing Li, et al.. (2016). Setting Priorities for Diabetic Retinopathy Clinical Research and Identifying Evidence Gaps. Ophthalmology Retina. 1(2). 94–102. 12 indexed citations

20.

Cox, Ben, et al.. (2009). Danio rerio in K-12 Classrooms: Sparking Interest in the New Generation of Scientists. Zebrafish. 6(2). 145–160. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact